Blazing a Trail: A Public Health Research Agenda in Genomics and Chronic Disease by McBride, Colleen M
VOLUME 2: NO. 2 APRIL 2005
Blazing a Trail: A Public Health Research
Agenda in Genomics and Chronic Disease
EDITORIAL
Suggested citation for this article: McBride CM. Blazing a
trail: a public health research agenda in genomics and
chronic disease. Prev Chronic Dis [serial online] 2005 Apr
[date cited]. Available from: URL: http://www.cdc.gov/
pcd/issues/2005/apr/05_0008.htm.
Whether and when genomics will lead to public
health benefit via reductions in chronic disease burden
has provided fodder for debate (1,2). A point of agree-
ment among both proponents and skeptics is that
directing genomics research to achieve this end will
require integration of knowledge across multiple disci-
plines and levels of analysis (i.e., biological, behavioral,
social, and environmental) (3). Getting started on
building these collaborations while the territory is new
could temper the disciplinary hegemony that so often
presents formidable barriers to transdisciplinary
research (4). That said, when it comes to genomics,
which has been the bastion of bench scientists and
most recently epidemiologists, it may be especially
challenging to attract the array of chronic disease
researchers with expertise in health education, health
psychology, health services delivery, and community-
based intervention that will be critical to further this
research agenda.
Vociferous pessimism expressed by some scientific
leaders about the future application of genomic discov-
ery to public health improvements (2) may be scaring
off some public health scientists from pursuing
genomics research (5). As has been said, “mud sticks
whatever its veracity” (6). However, some public health
researchers (7) would contend that waiting until
genomic discovery is further along to get involved will
relegate us to the role of translators, stuck with 
disseminating the technologies that evolve, even if 
they are poorly suited to populations or limited in 
their impact on chronic disease outcomes. Indeed, 
public health scientists must be among the trailblazers
in step with or a step ahead of the science, with a voice
in directing genomics research toward public 
health benefit.
Unfortunately, the emerging public health research
agenda for chronic disease is giving relatively little consid-
eration to the future of genomic discovery (8). An informal
review of the American Journal of Public Health over the
past decade shows that from 1995 to 1999 only eight arti-
cles related to genetics were published, a number that
increased only to 22 between 2000 and 2004. Publications
related to obesity, another area recognized during the
same time to be important for chronic disease, increased
fivefold from 26 to 138.
So how do we enlist public health scientists in transdis-
ciplinary collaborations that further a public health
research agenda? First, it is time for a frame change. The
past decade’s research agenda was framed to anticipate
and protect the public from the potential negative ethical,
social, and psychological implications of genomic discov-
ery. Not surprisingly, scientists in the vanguard of this
research have been bioethicists, lawyers, and public policy
experts. To enlist public health researchers in genomics
research, the agenda must be reframed to understand the
practical and proximal benefits of genomics for chronic dis-
ease. Specifically, we should be figuring out how genomic
discovery might help us to address three persistent chal-
lenges for chronic disease prevention and management: 1)
reducing prevalent behavioral risk factors, 2) reducing dis-
parities in chronic disease outcomes, and 3) improving
chronic disease care delivery at reduced cost. Below I sug-
gest examples of research in genomics and chronic disease
that could galvanize the transdisciplinary research collab-
orations needed to address these challenges.
The opinions expressed by authors contributing to this journal do not necessarily reflect the opinions of the U.S. Department of Health and Human Services,
the Public Health Service, the Centers for Disease Control and Prevention, or the authors’ affiliated institutions. Use of trade names is for identification only
and does not imply endorsement by any of the groups named above.
www.cdc.gov/pcd/issues/2005/apr/05_0008.htm • Centers for Disease Control and Prevention 1
Colleen M. McBride, PhDVOLUME 2: NO. 2
APRIL 2005
Reducing prevalent behavioral risk factors
The predicted broad array of genetic susceptibility
tests that will identify populations and individuals at
increased risk of chronic disease raise myriad research
questions. Most notably, how can these tests and related
feedback be used to motivate adoption of risk-reducing
behaviors?
At the social environment level, public education about
genomics will be a priority. Fewer than half of Americans
are aware of currently available genetic testing for cancer
susceptibility (9). Not surprisingly, awareness is greatest
among the most highly educated. Contrast this to a recent
Institute of Medicine report suggesting that nearly half of
Americans cannot read complex text and may lack the
skills needed to evaluate the risks and benefits of health-
related technologies (10). Development and evaluation of
health education approaches for individuals with low lit-
eracy is needed generally, and testing strategies to com-
municate the complexity of genomic risk may be especial-
ly fertile ground for this research. The increasing direct-to-
consumer advertising of susceptibility testing and popular
press coverage of genomic discovery provide a number of
“interventions” and natural experiment opportunities for
exploring the public’s understanding of genomic risk and
examining factors that influence interest in testing and its
association with risk-reduction outcomes across different
target groups.
At an individual level, a number of social and psycholog-
ical theories support debate about whether genomic risk
information will be viewed as more motivational for risk-
factor reduction than other risk feedback (e.g., measure-
ment of blood pressure and cholesterol levels, family histo-
ry). Important questions remain about whether genetic
risk information can help us improve upon state-of-the-art
risk communications by personalizing risk in different or
more effective ways than current risk indicators.
An important challenge will be how to communicate
information on small incremental risk increases conferred
by emerging genetic markers for chronic disease risk.
Currently the little empiric evidence available on these
risk communications is confined to highly selected samples
of well-educated patients for genes that confer high levels
of risk. The increasing evidence base for common genetic
polymorphisms that interact with common environmental
risk factors to modestly increase chronic disease risk (e.g.,
GSTM1 for smoking-related diseases, PPARG for dia-
betes, COL1A1 for osteoporosis) offer research tools that
can be used now to understand broader populations’
response to genetic risk and to address other important
public health questions (11).
Three decades of research in developing and testing
behavior-change interventions for risk reduction tell us it
is unlikely that a genetic test result alone will prompt
behavior change. Yes, genetic test results might provide a
cue to action to be capitalized upon and integrated with
evidence-based multicomponent interventions already
shown to influence behavior change. Moreover, considera-
tion of who might be most interested in genetic testing and
their motivations for such testing also could be explored to
adapt intervention approaches accordingly.
Reducing disparities in chronic disease outcomes
The prediction that genomic discovery may enable
future population-risk stratification for chronic diseases
raises understandable uneasiness about the use of genetic
determinism to explain health disparities (12). This makes
it all the more important that research now test how to use
knowledge about the remarkable similarity of the human
genome across time, continents, and populations to inform
the discussion about what is social and what is biologic in
our constructions of race, ethnicity, and other social group-
ings; such research could help us begin to clarify the indi-
vidual and joint effects of these factors on chronic disease
outcomes and health disparities. Scientists now suggest
that at best, genetic predispositions may account for a
third or less of chronic disease mortality (13).
Communicating about the complex, probabilistic, and rel-
atively weaker role of genetics in chronic disease could nat-
urally open a dialogue about the stronger role of environ-
ment and, in turn, might be used to strengthen the poten-
cy of behavior-change interventions and to address the
socially determined causes of disparities.
There are many fascinating and critical research ques-
tions about what are the most effective methods to
increase the public’s skills for evaluating the relative con-
tribution of genetics to chronic disease outcomes, the falli-
bilities and strengths of genomics research, and to which
groups these interventions should be targeted (e.g., racial
or ethnic communities, patients, health care providers,
health insurers, journalists, bench scientists). Moreover,
how might these educational and skills-building interven-
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Methodological research also should be a priority. For
example, most of the large population genetics registries,
despite earnest efforts, have had poor minority represen-
tation (14). From a scientific perspective, the external
validity of study results based on these registries, as well
as their credibility to minority communities, is lessened.
Thus, it is critical now to evaluate different approaches to
recruitment for genetic studies that augment minority and
population-based recruitment. Moreover, exploring public
education interventions to improve study recruitment
could be a fruitful area of research. In this regard, research
might also explore whether genetic susceptibility testing
for chronic disease is viewed as a monolith, or whether
participation in genomic research related to population-
wide diseases (e.g., cancer, diabetes) and race- or ethnici-
ty-associated diseases (e.g., cystic fibrosis, sickle cell ane-
mia) are viewed differently by target groups.
Equal access to genomic technologies also will be
important to reducing disparities in chronic disease out-
comes. Again, getting started early will be critical if we
are to design technologies that have any potential for
dissemination (15). To this end, it is important to evalu-
ate genetic testing and feedback in naturalistic settings
such as public health clinics to better understand system
barriers and facilitators that must be considered as we
develop genomic technologies for broad-based dissemi-
nation (16). In each case, rigorous evaluation of delivery
approaches that increase the likelihood that genomic
technologies are accompanied by appropriate support
services and are affordable to individuals and/or systems
will be key to success.
Improving chronic disease care effectiveness and efficiency
Interventions to help patients manage the physical and
psychological consequences of their chronic conditions and
make requisite lifestyle changes have shown benefits for a
variety of patient and system-level outcomes (17). Yet
effective self-management involves trial and error, as clin-
ical recommendations are based on broad and heteroge-
neous phenotypes of chronic disease. An important ques-
tion is whether genetically customized management rec-
ommendations could improve patient self-management of
chronic illness above current standard-of-care approaches.
For example, psychological theories tell us it is plausible
and testable that genetically customized self-management
interventions might empower patients to be better self-
managers and consumers of health care. Accordingly,
genetic tailoring might improve patient–provider relation-
ships in ways that reduce visit time and follow-up needs.
Additionally, we might ask what genetic information
patients and providers need to make them better collabo-
rators. Answers to these questions “upstream” might be
used to direct bench science to genomics research where
products have the best potential for dissemination to these
target groups.
Also important to consider is that health care providers
are expected to deliver an increasing number of preven-
tive services during their visits with patients (18). Thus,
the potential for genomic risk stratification to enable effi-
ciencies in health care delivery that reduce cost without
compromising care is an important area for research.
Research related to current genetic testing applications
(e.g., BRCA1, BRCA2, hereditary nonpolyposis colorectal
cancer [HNPCC]) has been conducted in specialized care
settings where certified genetic counselors provide one- to
three-hour sessions to support patient decision making
and communicate test results. This research tells us little
about how these applications might be incorporated into
primary care or community health settings. Evaluating
different counseling delivery models that have been
shown in previous health promotion research to be effec-
tive (e.g., lay advisors, telephone counseling, Web-based
information) is a good place to start. This evaluation will
require us to involve genetic counselors to balance what is
best practice for communicating about chronic disease
markers against what can be effectively integrated into a
variety of care settings.
Cost also will be important to consider. Current studies
have shown some pharmacogenomic interventions to be
worth the cost, but these studies are too few in number to
evaluate the implications of genomic medicine broadly (19).
The importance of research for evaluating the interven-
tions that might be most cost-effective upstream of genom-
ic technology development cannot be overstated (19).
What do we need to move forward a public health
research agenda?
Special journal editions like this one and the research
that is highlighted is a good start. Bringing the theme of
genomics to national public health and behavioral medi-
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cine meetings and featuring public health scientists in the
vanguard of this research from the Public Health
Genomics Centers, funded by the Centers for Disease
Control and Prevention, and the Centers of Excellence for
ELSI Research, funded by the National Institutes of
Health, as keynote speakers also could increase buy-in.
The slower pace of genomic discovery in chronic disease
means that for the time being we will be using imperfect
genomic-risk prototypes (20). Certainly, we must have
standards for choosing which prototypes to evaluate (e.g.,
meta-analyses as an evidence base) but not hold them now
to standards such as clinical validity or utility that ulti-
mately may be the goal for dissemination. Indeed, why put
the cart before the horse if the technologies in their proto-
typic form cannot accomplish goals that will affect public
health outcomes? Genome scientists, clinicians, and pub-
lic health researchers could collaborate in developing
working standards for selecting promising genomic-risk
applications to be used in chronic disease research. It will
be important to secure buy-in for this research from insti-
tutional review boards that may be uncomfortable with
the use of experimental genomic technologies in public
health and clinical settings.
Compromising on prototypes does not mean that our
research should compromise on rigor. It is time to move
beyond descriptive and exploratory studies to conceptual-
ly based, hypothesis-driven public health research. Public
health researchers have a trailblazing role to play in these
earliest phases of framing an agenda for genomics
research that puts public health challenges front and cen-
ter. The time for action is now!
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